Crohn’s Disease Clinical Trial Enrollment Complete
QBECO SSI Clinical Trial for Ulcerative Colitis Enrollment Complete
Our clinical trial for ulcerative colitis is now complete.Read More
QBECO SSI Treatment
QBECO SSI is derived from components of inactivated E. coli.Read More
Qu Biologics Site Specific Immunomodulators
Dr. Hal Gunn talks about Site Specific Immunomodulators (SSIs), investigational new treatments for IBD. Dr. Gunn talks about Qu Biologics’ research of immune system dysfunction and how SSIs, which are derived from inactivated bacterial components, may stimulate an innate immune response in the GI tract to reverse the underlying chronic bacterial infection/dysbiosis related to IBD.
About Qu Biologics’ Ulcerative Colitis Clinical Trial
Qu Biologics’ Clinical Operations Associate, Samantha Green, explains what to expect in the ulcerative clinical trial.
IBD Clinical Trial Information for Gastroenterologists
Qu Biologics’ CEO, Dr. Hal Gunn, talks about the research behind QBECO SSI and how this investigational treatment is designed to resolve the underlying trigger for Crohn’s disease and ulcerative colitis.